These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 11085367)

  • 1. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Maekawa C; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Nov; 23(11):1363-9. PubMed ID: 11085367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Sawada S; Nishide T; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Jan; 23(1):87-96. PubMed ID: 10706418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats.
    Hanada E; Ohtani H; Kotaki H; Sawada Y; Sato H; Iga T
    J Pharm Sci; 1999 Feb; 88(2):234-40. PubMed ID: 9950644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability.
    Miyazaki M; Mukai H; Iwanaga K; Morimoto K; Kakemi M
    J Pharm Pharmacol; 2001 Sep; 53(9):1235-46. PubMed ID: 11578106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective pharmacokinetics and pharmacodynamics of disopyramide and its metabolite in rabbits.
    Horikawa M; Yasumuro M; Kanno M; Hanada K; Hashiguchi M; Ogata H
    J Pharm Pharmacol; 2001 Dec; 53(12):1621-8. PubMed ID: 11804392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption.
    Pao LH; Zhou SY; Cook C; Kararli T; Kirchhoff C; Truelove J; Karim A; Fleisher D
    Pharm Res; 1998 Feb; 15(2):221-7. PubMed ID: 9523307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
    Bryson SM; Whiting B; Lawrence JR
    Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model.
    Miki A; Ohtani H; Sawada Y
    J Clin Pharm Ther; 2011 Dec; 36(6):642-50. PubMed ID: 21143257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of absorption rate of alpha-human atrial natriuretic peptide from the plasma profile and diuretic effect after intranasal administration to rats.
    Miyamoto M; Tsukune T; Hori S; Hayashi T; Natsume H; Sugibayashi K; Morimoto Y
    Biopharm Drug Dispos; 2001 May; 22(4):137-46. PubMed ID: 11745916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Bramuglia GF; Höcht C
    J Pharmacol Toxicol Methods; 2007; 56(3):290-9. PubMed ID: 17560132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of the disopyramide concentration-effect relationship.
    Whiting B; Holford NH; Sheiner LB
    Br J Clin Pharmacol; 1980 Jan; 9(1):67-75. PubMed ID: 7356895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Normal" response of the QT interval and QT dispersion following intravenous injection of the sodium channel blocker disopyramide: methodological aspects.
    Nowinski K; Bergfeldt L
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):573-80. PubMed ID: 8547207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide.
    Phillips L; Grasela TH; Agnew JR; Ludwig EA; Thompson GA
    Clin Pharmacol Ther; 2001 Oct; 70(4):370-83. PubMed ID: 11673753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.
    Le Coz F; Funck-Brentano C; Morell T; Ghadanfar MM; Jaillon P
    Clin Pharmacol Ther; 1995 May; 57(5):533-42. PubMed ID: 7768076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs.
    Ollerstam A; Visser SA; Persson AH; Eklund G; Nilsson LB; Forsberg T; Wiklund SJ; Gabrielsson J; Duker G; Al-Saffar A
    J Pharmacol Toxicol Methods; 2006; 53(2):174-83. PubMed ID: 16140023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model.
    Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP
    Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man.
    Jou MJ; Huang SC; Kiang FM; Lai MY; Chao PD
    J Pharm Pharmacol; 1997 Nov; 49(11):1072-5. PubMed ID: 9401940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.